SLRX: Salarius Pharmaceuticals, Inc. Stock

by  •  • Comments Off on SLRX: Salarius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 16.72
Enterprise Value ($M) 12.46
Book Value ($M) 3.65
Book Value / Share 0.76
Price / Book 4.58
NCAV ($M) 3.60
NCAV / Share 0.75
Price / NCAV 4.65

Profitability (mra)
Return on Invested Capital (ROIC) -2.37
Return on Assets (ROA) -0.74
Return on Equity (ROE) -1.06

Liquidity (mrq)
Quick Ratio 3.91
Current Ratio 3.91

Balance Sheet (mrq) ($M)
Current Assets 4.83
Assets 4.88
Liabilities 1.23
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -12.89
Net Income -12.54
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -12.85
Cash from Investing 0.00
Cash from Financing 6.64

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
10-27 13D Lee Elvin Sanghwan 6.09

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPOR
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1)
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 344,052 1,117,058 30.80
2024-07-25 11,138,291 31,061,929 35.86
2024-07-24 337,982 1,231,718 27.44
2024-07-23 22,150,321 59,733,396 37.08
2024-07-22 126,673 520,407 24.34

(click for more detail)

Similar Companies
SCLX – Scilex Holding Company SEEL – Seelos Therapeutics, Inc.
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SLS – SELLAS Life Sciences Group, Inc.
SMFL – Smart for Life, Inc.


Financial data and stock pages provided by
Fintel.io